Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Xavier LeleuGuillemette FouquetValentine RichezStéphanie GuidezAlain DuhamelFrançois MachuronLionel KarlinBrigitte KolbMourad TiabCarla AraujoNathalie MeulemanJean-Valère MalfusonPascal BourquardPascal LenainMurielle RousselArnaud JaccardMarie-Odile PétillonKarim Belhadj-MerzougGérard LepeuMarie-Lorraine ChrétienJean FontanPhilippe RodonAnna SchmittFritz OffnerLaurent VoillatSophie CerejaFrédérique KuhnowskiSophie RigaudeauOlivier DecauxCatherine Humbrecht-KrautJamile FrayferOlivier FitoussiDamien RoosweilJean-Claude EisenmannVéronique DorvauxEric G VoogMichel AttalPhilippe MoreauHervé Avet-LoiseauCyrille HulinThierry FaconPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The MTD dose of carfilzomib was 70 mg/m2 in this KMP weekly study in eNDMM. Response rates, and especially CR rate, were remarkable in this population, and would benefit from being assessed in a larger-scale study. The IFM2012-03 study demonstrated that the MTD of carfilzomib weekly is 70 mg/m2 in eNDMM, and 56 mg/m2 for patients older than 75 years. Carfilzomib used weekly in combination has a good efficacy and safety profile in eNDMM.